pharma · Head and Neck Neoplasms · Rheumatoid Arthritis
Chinese University of
Chinese University of Hong Kong
Chinese University of clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- CN
- Programs
- 42
- Drugs
- 55
- Patents
- 0
Chinese University of projects
9 ClinicalTrials.gov programs sponsored by Chinese University of.
Chinese University of has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
115
Chinese University of Hong Kong
Essential Hypertension
1 trial -
Baricitinib 4 MG
Chinese University of Hong Kong
Rheumatoid Arthritis
1 trial -
CSSN-6091-DaweiLiu
Chinese University of Hong Kong
Shock, Septic
1 trial -
Finerenone
Chinese University of Hong Kong
Patients With Type 2 Diabetes
1 trial -
Pegyinterferon-alfa-2a
Chinese University of Hong Kong
Chronic Hepaititis B
1 trial -
Sodium valproate
Chinese University of Hong Kong
Epilepsy
1 trial -
film dressing by adhesive
Chinese University of Hong Kong
Chronic Peritoneal Dialysis
1 trial -
inactivated EV71 vaccine (KMB-17 cells)
Chinese University of Hong Kong
Hand, Foot and Mouth Disease (HFMD)
1 trial -
tacrolimus
Chinese University of Hong Kong
Lupus Nephritis
1 trial
Frequently asked questions
How many clinical projects does Chinese University of have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.